Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in Advanced Malignant Tumors
NCT05170958Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in solid tumor (advanced stage), sponsored by Leads Biolabs. Started Jan 2022; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05170958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170958.